Welcome to our dedicated page for Imax SEC filings (Ticker: IMAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IMAX Corporation (NYSE: IMAX) files reports and disclosure documents with the U.S. Securities and Exchange Commission that provide detail on its entertainment technology business, capital structure, and material events. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe the company’s convertible notes, credit facilities, and operating results.
Among its recent filings, IMAX has reported the entry into a Seventh Amended and Restated Credit Agreement, which increased its revolving borrowing capacity and set out leverage covenants, guarantees, and use of proceeds. The company has also filed an 8-K describing the issuance of 0.75% convertible senior notes due 2030, outlining interest terms, maturity, conversion rights, redemption conditions, and related capped call transactions intended to reduce potential dilution or offset certain cash payments upon conversion.
Investors reviewing IMAX filings can use this page to access documents that discuss the company’s financial obligations, including convertible debt, revolving credit facilities, and related covenants. Filings also reference IMAX’s global footprint, with systems operating in multiple countries and territories, and its listing on the New York Stock Exchange under the symbol IMAX.
Stock Titan’s SEC filings page for IMAX provides real-time access to new submissions from the EDGAR system, along with AI-powered summaries designed to explain the key terms and implications of complex filings. Users can quickly identify items related to financing transactions, results of operations, and other material corporate developments, and can locate information relevant to topics such as note conversion features, redemption provisions, and reporting covenants.
IMAX Corp filed a Form 144 to notify a proposed sale of 20,000 Class A Common Shares through Merrill Lynch on the NYSE with an approximate sale date of 09/15/2025. The filing reports an aggregate market value of $656,029 against 53,782,520 shares outstanding, indicating the sale represents a small fraction of the company's outstanding stock.
The 20,000 shares were acquired through vesting of restricted stock units (RSUs) issued as compensation on dates between 02/21/2018 and 03/07/2021 (2,456; 1,869; 15,203; 472 respectively). No securities sales by the filer in the past three months are reported, and the filer certifies no undisclosed material adverse information.
Kenneth Ian Weissman, IMAX Corp executive (Deputy General Counsel, Corporate Secretary & Chief Compliance Officer), reported option exercise and subsequent share sales on 08/14/2025. He exercised 7,072 stock options with an exercise price of $22.49 (options issued in 2019, expiring 03/07/2026) converting them into 7,072 common shares. The filing shows two dispositions the same day: sale of 7,072 shares at $25.6707 and sale of 8,000 shares at $25.6272.
Ownership changed from an opening balance of 34,133 common shares to a post-transaction balance of 26,133 common shares. The filing notes Mr. Weissman retains 17,021 restricted share units outstanding and that the exercised options were vested in installments between 2020 and 2023.
Form 144 notice for IMAX (IMAX) reports a proposed sale of 15,072 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $386,560.79 based on 53,782,520 shares outstanding. The approximate sale date is 08/14/2025 on the NYSE. The lots to be sold were largely acquired through restricted stock vesting on 03/07/2023 (multiple grants totaling 8,867 shares) and earlier vesting on 03/07/2021 (233 shares), plus an option exercise scheduled 08/14/2025 for 7,072 shares paid in cash. The filer states no securities of the issuer were sold in the past three months and attests they are not aware of undisclosed material adverse information.
Schedule 13G/A filed for IMAX Corp reports that Orbis Investment Management Limited and Allan Gray Australia Pty Ltd beneficially own a combined 5,113,033 shares of IMAX common stock (CUSIP 45245E109), representing 9.5% of the class. Orbis individually holds 5,093,213 shares with sole voting and dispositive power; Allan Gray Australia holds 19,820 shares. The filing lists Orbis (Bermuda) and Allan Gray Australia (Australia) as the reporting persons.
The statement is filed under a Schedule 13G/A and includes certifications that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of IMAX. The filing is signed by Matt Gaarder as Attorney-in-Fact with signature date 08/14/2025. The event date requiring the filing is noted as 06/30/2025.